In a collaboratively funded government effort advancing treatments for the Zika virus, scientists recently announced that an exploratory version of the Zika purified inactivated virus (ZPIV) proved safe, tolerated and effective in national study participants.
GlaxoSmithKline plc (GSK) recently announced evidence supporting the potential for Shingrix, a shingles vaccine, for people age 18 and older who have undergone autologous haematopoietic stem cell transplant.
Researchers from Wake Forest Institute for Regenerative Medicine have found that bioengineered artificial ovaries may offer a safer and more natural hormone replacement therapy for women and can also improve bone and uterine health.
A study by researchers from the University of Pennsylvania's Perelman School of Medicine shows that despite an increased cost, digital breast tomosynthesis (DBT), or 3-D mammography, is a more effective screening tool than digital mammography (DM) and can actually control cancer-screening costs.
Clinical-stage biotechnology company Pieris Pharmaceuticals Inc.’s Anticalin treatment suite to combat cancer, respiratory conditions and other maladies, recently obtained approval from Australian authorities to commence a first-time study for PRS-060/AZD1402, an inhaled treatment targeting asthma.
National Institutes of Health (NIH) and Case Western Reserve University School of Medicine researchers have released a study raising concerns over the transmission of prion diseases such as Creutzfeldt-Jakob disease (CJD) through the skin.
A recent study by researchers at the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center shows cognitive computing can help doctors find more clinical trials and therapeutic options for their cancer patients based on the genetic makeup of their tumors.
AstraZeneca and MedImmune, its department for global biologics research and development, recently gave 28 presentations at the American Heart Association (AHA) Scientific Sessions, which took place Nov. 11-15 in Anaheim, California.
Scientists from the University of North Carolina (UNC) and North Carolina State University have developed a melanin-enhanced cancer immunotherapy treatment that boosts a naturally occurring immune response against skin cancer cells in mice.